| Contributors: |
Cherubini, V.; Fargalli, A.; Arnaldi, C.; Bassi, M.; Bonfanti, R.; Patrizia Bracciolini, G.; Cardella, F.; Dal Bo, S.; Delvecchio, M.; Di Candia, F.; Franceschi, R.; Maria Galassi, S.; Gallo, F.; Graziani, V.; Iannilli, A.; Mameli, C.; Marigliano, M.; Minuto, N.; Monti, S.; Mozzillo, E.; Pascarella, F.; Predieri, B.; Rabbone, I.; Roppolo, R.; Schiaffini, R.; Tiberi, V.; Tinti, D.; Toni, S.; Scaramuzza, A.; Vestrucci, B.; Gesuita, R. |
| Description: |
Aims: To analyze metabolic outcomes, diabetes impact and device satisfaction in children and adolescents with type 1 diabetes in Italy who used different treatment modalities for diabetes care in a real-life context. Methods: In this multicenter, nationwide, cross-sectional study, 1464 participants were enrolled at a routine visit. The following treatment modalities were considered MDI + SMBG; MDI + CGM; Sensor Augmented Pump Therapy; predictive management of low glucose; Hybrid Closed Loop (HCL); Advanced Hybrid Closed Loop (AHCL). Health related quality of life was evaluated by the Italian version of the Diabetes Impact and Device Satisfaction Scale (DIDS) questionnaire. Results: Patients treated with AID systems were more likely to have HbA1c ≤ 6.5 %, higher percentage of time with glucose levels between 70 and 180 mg/dL, lower percentage of time with glucose levels above 180 mg/dL, higher device satisfaction, and reduced impact of diabetes. All the therapeutic modalities with respect to MDI + CGM, except for MDI + SMBG, contributed to increase the device satisfaction. HCL and AHCL respect to MDI + CGM were associated with lower diabetes impact. Conclusion: Real-life use of automated insulin delivery systems is associated with reduced type 1 diabetes impact, increased device satisfaction, and achievement of glycemic goals. |